Faculty Bibliography

Management of blood pressure (BP) abnormalities in patients with autonomic failure is usually based on office BP readings. It is uncertain, whether office readings reflect actual BP's [corrected] during a typical day. Therefore, in 45 patients with autonomic failure, we compared office BP values during a tilt test with those captured on a 24-h BP [corrected] ambulatory monitor. Office BP values while supine predicted well the level of nighttime hypertension. However, in only 33% of patients, office values during tilt test accurately reflected hypotension during a typical day. Therefore, BP [corrected] ambulatory monitoring is useful to gauge the true severity of hypotension in patients with autonomic failure.

Hereditary sensory and autonomic neuropathy type III (HSAN III, Riley-Day syndrome, Familial Dysautomia) is characterised by elevated thermal thresholds and an indifference to pain. Using microelectrode recordings we recently showed that these patients possess no functional stretch-sensitive mechanoreceptors in their muscles (muscle spindles), a feature that may explain their lack of stretch reflexes and ataxic gait, yet patients have apparently normal low-threshold cutaneous mechanoreceptors. The density of C-fibres in the skin is markedly reduced in patients with HSAN III, but it is not known whether the C-tactile afferents, a distinct type of low-threshold C fibre present in hairy skin that is sensitive to gentle stroking and has been implicated in the coding of pleasant touch are specifically affected in HSAN III patients. We addressed the relationship between C-tactile afferent function and pleasant touch perception in 15 patients with HSAN III and 15 age-matched control subjects. A soft make-up brush was used to apply stroking stimuli to the forearm and lateral aspect of the leg at five velocities: 0.3, 1, 3, 10 and 30cm/s. As demonstrated previously, the control subjects rated the slowest and highest velocities as less pleasant than those applied at 1-10cm/s, which fits with the optimal velocities for exciting C-tactile afferents. Conversely, for the patients, ratings of pleasantness did not fit the profile for C-tactile afferents. Patients either rated the higher velocities as more pleasant than the slow velocities, with the slowest velocities being rated unpleasant, or rated all velocities equally pleasant. We interpret this to reflect absent or reduced C-tactile afferent density in the skin of patients with HSAN III, who are likely using tactile cues (i.e. myelinated afferents) to rate pleasantness of stroking or are attributing pleasantness to this type of stimulus irrespective of velocity.

Multiple system atrophy (MSA) is a neurodegenerative disease with two motor phenotypes: parkinsonian (MSA-P) and cerebellar (MSA-C). To elucidate whether in addition to the motor abnormalities there are other significant differences between these phenotypes, we performed a retrospective review of 100 patients (61 males, 39 females) with a diagnosis of possible (12 %), or probable (88 %) MSA. Four patients eventually had post-mortem confirmation (i.e., definite MSA). Sixty percent were classified as having MSA-P and 40 % as MSA-C. MSA-C and MSA-P patients had similar male prevalence (60 %), age of onset (56 +/- 9 years), and frequency of OH (69 %). Brain MRI abnormalities were more frequent in MSA-C patients (p < 0.001). Mean survival was 8 +/- 3 years for MSA-C and 9 +/- 4 years for MSA-P patients (p = 0.22). Disease onset before 55 years predicted longer survival in both phenotypes. Initial autonomic involvement did not influence survival. We conclude that patients with both motor phenotypes have mostly similar survivals and demographic distributions. The differences here identified could help counseling of patients with MSA.

To define the retinal phenotype of subjects with familial dysautonomia (FD). A cross-sectional study was carried out in 90 subjects divided in three groups of 30 each (FD subjects, asymptomatic carriers and controls). The study was developed at the Dysautonomia Center, New York University Medical Center. All subjects underwent spectral domain optical coherence tomography (OCT) and full neuro-ophthalmic examinations. In a subset of affected subjects, visual evoked potentials and microperimetry were also obtained. We compared the retinal nerve fiber layer (RNFL) thickness from OCT between the three groups. OCT showed loss of the RNFL in all FD subjects predominantly in the maculopapillary region (63 % temporally, p < 0.0001; and 21 % nasally, p < 0.005). RNFL loss was greatest in older FD subjects and was associated with decreased visual acuity and color vision, central visual field defects, temporal optic nerve pallor, and delayed visual evoked potentials. Asymptomatic carriers of the FD gene mutation all had thinner RNFL (12 % globally, p < 0.005). OCT and clinical neuro-ophthalmological findings suggest that maculopapillary ganglion cells are primarily affected in FD subjects, leading to a specific optic nerve damage that closely resembles mitochondrial optic neuropathies. This raises the possibility that reduced IKAP levels may affect mitochondrial proteins and their function in the nervous system, particularly in the retina.

Spinal pseudomeningoceles are extramural cerebrospinal fluid (CSF) collections that communicate with the CSF space around the spinal cord. We describe an 81-year-old man who presented with recurrent episodes of brief loss of consciousness (LOC) and collapse following an L3-4 discectomy complicated by the development of a spinal pseudomeningocele containing approximately 200 cc of CSF (as determined by MRI). LOC occurred both when standing and when the pseudomeningocele in his back was compressed when laying down. Transcranial Doppler (TCD) of his right middle cerebral artery (MCA) during manual compression of the pseudomeningocele (in the sitting position) showed maintained systolic but absent diastolic blood flow while systemic blood pressure was unchanged. When standing, TCD of the MCA showed similar findings and a small fall in systemic blood pressure. The absence of blood pressure changes and the observed TCD pattern in the MCA, which is consistent with collapse of the artery during diastole, suggest that the episodes of loss of consciousness were due to increased intracranial pressure (ICP). Increased ICP is easily explained as a result of displacement of CSF from the pseudomenigocele towards the cranium. Standing, however, should cause a reduction in ICP as CSF could travel down towards the lumbar pseudomeningocele. Possible explanations of increased ICP while standing include involuntary Valsalva-like maneuver similar to "cough syncope," mechanical obstruction preventing CSF outflow, or external compression of the pseudomeningocele by extensor back muscles. In patients with syncopal episodes following discectomies the possibility of a pseudomeningocele should be considered

Afferent baroreflex failure occurs in the genetic disorder familial dysautonomia (FD) and in patients with acquired lesions of the afferent baroreflex pathways. Afferent baroreflex failure is characterized by extremely labile blood pressure, with paroxysmal hypertension due to unrestrained norepinephrine release, which may result in targetorgan damage. These hypertensive episodes are traditionally managed with the alpha-2-receptor agonist clonidine, but this produces profound hypotension, fatigue and rebound hypertension. Carbidopa is a competitive reversible inhibitor of the enzyme dopa-decarboxylase that does not cross the blood brain barrier. Here we examined the effect of carbidopa on norepinephrine production and blood pressure variability in 12 patients with FD and 3 with acquired afferent baroreflex failure. Patients underwent a 24-h urine collection and simultaneous ambulatory blood pressure monitoring at baseline (pretreatment) and while taking carbidopa. Catecholamine excretion was measured using high performance liquid chromatography (HPLC). Blood pressure variability was calculated from the standard deviation of blood pressure values captured at 20-min intervals during waking hours. Mean dose of carbidopa was 500 mg per day. Compared to baseline, carbidopa significantly reduced norepinephrine excretion (32 +/- 9 vs. 12 +/- 1 lg/gCr, p<0.001) and blood pressure variability (25 +/- 3 vs. 19 +/- 3 mmHg, p<0.03). Carbidopa reduced the highest blood pressure value captured on ambulatory monitoring from 175 +/- 6 to 155 +/- 9 mmHg (p<0.03), while the lowest captured blood pressure values were similar pre and post-treatment. Carbidopa inhibits the downstream production of norepinephrine and is a novel approach to treating paroxysmal hypertension in patients with genetic or acquired afferent baroreflex failure

Familial dysautonomia (FD) is caused by a splicing error in the IKBKAP gene that encodes human Elongator protein-1 (ELP-1). In these patients, exon 20 is frequently skipped duringmRNA splicing, but cells retain the ability to produce a lowlevel of normal (wild-type) IKBKAPmRNAand normal protein. Phosphatidylserine (PS, Sharp-thought), an acidic phospholipid, has been shown to raise elongator protein-1 levels by increasing IKBKAPtranscription in fibroblast cell-lines derived fromFD patients and, more recently, in a mouse model of FD. Given that PS is available over the counter, weconducted a study to determinewhether PS raises IKBKAP gene expression in patients with FD. We enrolled 7 patients with FD, 16-23 years old, in an open-label titration protocol. Patients were examined at baseline (visit 1), after 2 months of taking 300 mg/day (visit 2) and again after 2 months of taking 600 mg/day of PS(visit 3).Bloodwas taken at each visit. Sampleswere de-identified and investigators blinded to the sample identity. Blood was treated with Tri- Reagent, and RNA extracted according to manufacturers specifications. Quantitative polymerase chain reaction (qPCR) was performed to measure the level of normal IKBKAPmRNA. PSwas well tolerated and there were no adverse events or unexpected laboratory abnormalities. After 2 months of taking 300 mg of PS per day, there was a trend for IKBKAP mRNA levels to increase. After 2 months of 600 mg of PS per day, IKBKAPmRNAexpression increased between 2 and 8 fold in all but one patient (p<0.01). Our results indicate that PS safely raises wild-type IKBKAP mRNA levels in blood from patients with FD, opening an exciting potential therapeutic path for treatment. Clinical trials to determine whether restoring Elongator protein 1 levels impacts the phenotype are underway

BACKGROUND: Hereditary sensory and autonomic neuropathy type III features marked ataxic gait that progressively worsens over time. We assessed whether proprioceptive disturbances can explain the ataxia. METHODS: Proprioception at the knee joint was assessed using passive joint angle matching in 18 patients and 14 age-matched controls; 5 patients with cerebellar ataxia were also studied. Ataxia was quantified using the Brief Ataxia Rating Score, which ranged from 7 to 26 of 30. RESULTS: Neuropathy patients performed poorly in judging joint position: mean absolute error was 8.7 degrees +/- 1.0 degrees , and the range was very wide (2.8 degrees -18.1 degrees ); conversely, absolute error was only 2.7 degrees +/- 0.3 degrees (1.6 degrees -5.5 degrees ) in the controls and 3.0 degrees +/- 0.2 degrees (2.1 degrees -3.4 degrees ) in the cerebellar patients. This error was positively correlated to the degree of ataxia in the neuropathy patients but not the cerebellar patients. CONCLUSIONS: These results suggest that poor proprioceptive acuity at the knee joint is a major contributor to the ataxic gait associated with hereditary sensory and autonomic neuropathy type III.

OBJECTIVE: The purpose of this study was to determine whether carbidopa (Lodosyn), an inhibitor of dopa-decarboxylase that blocks the synthesis of dopamine outside the brain, is an effective antiemetic in patients with familial dysautonomia (FD) and hyperdopaminergic nausea/retching/vomiting attacks. METHODS: We enrolled 12 patients with FD in an open-label titration and treatment study to assess the safety of carbidopa. We then conducted a randomized, double-blind, placebo-controlled, crossover study to evaluate its antiemetic efficacy. RESULTS: Previous fundoplication surgery in each patient studied prevented vomiting, but all of the subjects experienced severe cyclical nausea and uncontrollable retching that was refractory to standard treatments. Carbidopa at an average daily dose of 480 mg (range 325-600 mg/day) was well tolerated. In the double-blind phase, patients experienced significantly less nausea and retching while on carbidopa than on placebo (p < 0.03 and p < 0.02, respectively). Twenty-four-hour urinary dopamine excretion was significantly lower while on carbidopa (147 +/- 32 microg/gCr) than while on placebo (222 +/- 41microg/gCr, p < 0.05). CONCLUSIONS: Carbidopa is a safe and effective antiemetic in patients with FD, likely by reducing the formation of dopamine outside the brain. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that carbidopa is effective in reducing nausea/retching/vomiting in patients with FD.